DDInter129 DDInter899
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Atazanavir {u} (Compound) binds {v} (Gene) ABCB1
Atazanavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Atazanavir {u} (Compound) causes {v} (Side Effect) Pelvic pain
Atazanavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Abiraterone
Atazanavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Caffeine
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Methylprednisolone
Atazanavir (Compound) resembles Ritonavir (Compound)
Atazanavir (Compound) binds ABCB1 (Gene)
Atazanavir (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Atazanavir (Compound) causes Pelvic pain (Side Effect)
Atazanavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Atazanavir may cause a minor interaction that can limit clinical effects when taken with Caffeine
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene
Atazanavir may lead to a major life threatening interaction when taken with Venetoclax
Atazanavir may lead to a major life threatening interaction when taken with Methylprednisolone